The Biden administration has proposed a new set of rules that would expand the list of prescription drugs subject to Medicare price negotiations. If finalized, the rules would add 30 additional medications to the negotiation program by 2028.
The proposal targets drugs with the highest total Medicare spending, including treatments for cancer, autoimmune conditions, and rare diseases. The administration estimates the changes would save Medicare $18 billion annually once fully implemented.
Pharmaceutical industry groups have signaled they will challenge the expansion in court, arguing it exceeds the authority granted by Congress.
